Psychiatry

Paul Ruberg, PA-C, presents a patient case and discusses the importance of educating patients and about the treatment process.

Merrideth Leggat, MD, reviews clinical and practical implications of findings from the TRANSFORM and SUSTAIN studies exploring the utility of esketamine in the treatment of TRD.

Ryan J. Wakim, MD, DFAPA, explores the causes and diagnostic criteria for treatment resistant depression. He also discusses the importance of comprehensive assessment and personalized approaches to care.

Dr. Levine talks with Marketa Wills, MD, about the role of the payer in medicine.

The LYNX drug development platform is able to deliver drug consistently, while minimizing peaks and troughs of drug levels compared to daily medicine.

Depression is linked with an increased incidence of multiple nonoverlapping physical conditions requiring hospital treatment, including endocrine, musculoskeletal, and vascular diseases.

Clozapine treatment may offer the added benefit of improved sleep in patients with schizophrenia, according to a meta-analysis.

According to the study, gay and bisexual adolescents show higher rates of sleep issues and sleep disturbances.

The extended-release injectable suspension treatment represents the first subcutaneous, long-acting formulation of risperidone.

The long-acting injectable can be administered once every 2 months to either treat schizophrenia or serve as a maintenance monotherapy for bipolar disorder.

An analysis of data from more than 119,000 pregnancies suggests women with prenatal depression were at increased risk for multiple forms of cardiovascular disease within the first 2 years following delivery relative to their counterparts without prenatal depression.

Treatment with benzodiazepines, antipsychotics, and antidepressants was associated with an increased risk of all-cause hospitalization or mortality, while mood stabilizer treatment did not have a statistically significant association with any of the predetermined outcomes and ADHD medications were linked to a lower risk of psychiatric hospitalization.

New research highlights the shared and unique characteristics of sleep and rest-activity rhythm measures among patients with schizophrenia.

There was an increase in depression in the cystic fibrosis group, as well as an increase in anxiety in cystic fibrosis caregivers during the pandemic.

For older adults, 19.4% of exposures resulted in death or other major outcomes and there were twice as many cases that involved children aged 5-13 years in 2021 compared to 2019.

Scores for the 20-Item Symptom Checklist improved from baseline over gestation in the interpersonal psychotherapy cohort, but not in the enhanced usual care group.

The results show depressive disorders in the first cohort were associated with a nearly 4-fold higher risk of depressive disorders in the spousal cohort.

A cross-sectional analysis of data is offering a snapshot of trends in the treatment of 7 common chronic health conditions among incarcerated populations in the US relative to the general population.

Evidence shows digital cognitive behavioral therapy for insomnia is more effective than medication therapy, with comparable effectiveness to combination therapy.

State adoption of both SNAP eligibility policies, where the state eliminates the asset test and increases the income limit resulted in decreases in the rates of past-year major depressive episodes, mental illness, serious mental illness, and suicidal ideation.

Electroconvulsive therapy was superior to ketamine in a sensitivity analysis of methodologically stronger trials and also was better in study-defined response and remission for patients with major depressive episodes.

A new study has found individuals with depression and insomnia show significantly less activity in the prefrontal cortex during verbal fluency tests, suggesting that sleep quality is an important indicator in fNIRS screening.

The risk of minor nuisances, violating APS law, and violating criminal law were higher in the nonadherence group.

The proportion of AUD treatment engagement did not differ between the 2 time periods, but intervention increased intermediate outcomes, including screening, new AUD diagnosis, and treatment initiation.